New Zomig Rapimelt Launched For Migraines
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




New Zomig Rapimelt Launched For Migraines

LISBON, PORTUGAL -- Sept. 9, 1999 -- AstraZeneca has launched the new Zomig rapimelt, a convenient melt-in-the-mouth tablet for the acute treatment of migraine.

The tablet melts within seconds on the tongue and enables patients to treat their migraine in situations where a drink of water may not be available.

Migraine is an extremely distressing, episodic, neurological disease which affects approximately 600 million people world-wide and can cause significant disability. It can strike at any time and sufferers may find themselves in situations where finding a glass of water to take a conventional tablet is impossible.

Even between attacks, when the migraine patient is symptom free, the fear of the next attack can have a serious impact on the sufferer's life and force them to modify their behaviour accordingly.

"Many patients express concern that they might suffer an attack in awkward situations," explained Dr. Sverker Nilsson, GP from Falkenberg, Sweden. "It is important that patients have treatments that they trust and find easy to take. The launch of Zomig rapimelt provides doctors with an opportunity to prescribe an easy, convenient migraine treatment for patients."

Related Links: Zomig and AstraZeneca.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities